Raft of Japanese approvals for Novartis
This article was originally published in Scrip
Novartishas received final approvals in Japan for four new products important to its business, following a series of positive recommendations in the latter months of last year. Xolair, Tasigna, Lucentis and Co-Dio are all now awaiting reimbursement price listing and should reach the market over the next few months.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.